Psoriasis Clinical Trials

Showing 781-800 of 1,026 trials

COMPLETEDPhase 3

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

NCT01206387

efficacy study in patients with moderate to severe plaque psoriasis.

Psoriasis

Sun Pharmaceutical Industries, Inc.120 participantsStarted Aug 2010

COMPLETEDPhase 2

A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

NCT00687362

Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22. The safety and efficacy of infliximab monotherapy will be evaluated.

Psoriasis

Merck Sharp & Dohme LLC22 participantsStarted May 2006

COMPLETEDPhase 3

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

NCT00251641

This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the treatment of moderate to severe psoriasis in adults who were diagnosed with moderate to severe plaque-type psoriasis for at least 6 months prior to screening (subjects with concurrent psoriatic arthritis may also be enrolled).

Psoriasis

Merck Sharp & Dohme LLC868 participantsStarted Sep 2005

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

Related Searches

LEO 32731 - A Phase I Study in Healthy Subjects

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis

Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Psoriatic Arthritis Treat to Target vs. Usual Care

Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis